The utility of a portable sleep monitor to diagnose sleep-disordered breathing in a pediatric population

Colin Massicotte RPSGT1, Suhail Al-Saleh MBBS FRCP MC2-1,2, Manisha Witmans MD FRCP FAASM1, Indra Narang BMedSci MBBH MD1-2


BACKGROUND: Central and/or obstructive sleep-disordered breathing (SDB) in children represents a spectrum of abnormal breathing during sleep. SDB is diagnosed using the gold standard, overnight polysomnography (PSG). The limited availability and access to PSG prevents its widespread use, resulting in significant delays in diagnosis and treatment of SDB. As such, portable sleep monitors are urgently needed.

OBJECTIVE: To evaluate the utility of a commercially available portable sleep study monitor (PSS-AL) (ApneaLink, ResMed, USA) to diagnose SDB in children.

METHODS: Children referred to a pediatric sleep facility were simultaneously monitored using the PSS-AL monitor and overnight PSG. The apnea-hypopnea index (AHI) was calculated using the manual and autoscoring function of the PSS-AL, and PSG. Sensitivity and specificity were compared with the manually scored PSS-AL and PSG. Pearson correlations and Bland-Altman plots were constructed.

RESULTS: Thirty-five children (13 female) completed the study. The median age was 11.0 years and the median body mass index z-score was 0.67 (range −2.3 to 3.8). SDB was diagnosed in 17 of 35 (49%) subjects using PSG. The AHI obtained by manually scored PSS-AL strongly correlated with the AHI obtained using PSG (r=0.89; P<0.001). Using the manually scored PSS-AL, a cut-off of AH1 of >5 events/h had a sensitivity of 94% and a specificity of 61% to detect any SDB diagnosed by PSG.

CONCLUSIONS: Although PSG is still recommended for the diagnosis of SDB, the ApneaLink sleep monitor has a role for triaging children referred for evaluation of SDB, but has limited ability to determine the nature of the SDB.

Key Words: Children; Polysomnography; Portable monitoring; Sleep-disordered breathing

SDB (4,5). There is currently an unprecedented increase in the syndrome) or secondary (eg, Arnold-Chiari malformations) (3). Iodic breathing or central hypoventilation are less common than OSA, with a reported prevalence of up to 60% (2). Central sleep apnea, periodic breathing and hypoventilation. The most common sleep disorder in children (OSA), characterized by snoring; recurrent, partial (ie, hypopneas) or complete obstruction (ie, apneas) of the upper airway; intermittent oxyhemoglobin desaturations; and sleep disruption. OSA affects 1% to 4% of all healthy children (1), with peak presentation at two to eight years of age, coinciding with adenotonsillar hypertrophy, the most common sleep disorder in children (OSA), characterized by snoring; recurrent, partial (ie, hypopneas) or complete obstruction (ie, apneas) of the upper airway; intermittent oxyhemoglobin desaturations; and sleep disruption. OSA affects 1% to 4% of all healthy children (1), with peak presentation at two to eight years of age, coinciding with adenotonsillar hypertrophy, the most common etiological factor for OSA (1). More recently, the epidemic of obesity has highlighted childhood obesity as a significant risk factor for OSA, with a reported prevalence of up to 60% (2). Central sleep apnea, periodic breathing or central hypoventilation are less common than OSA, and can be classified as primary (eg, congenital central hypoventilation syndrome) or secondary (eg, Arnold-Chiari malformations) (3).

The standard gold test to diagnose SDB is polysomnography (PSG), which is an important tool to differentiate the various types of SDB (4,5). There is currently an unprecedented increase in the demand for testing for SDB due to an increasing awareness of pediatric sleep disorders, in particular, obesity-related OSA; the recognition of adverse consequences of SDB on cardiovascular, metabolic and neuropsychological functions as well as the quality of life of children with SDB (6-10); and recommendations for preoperative monitoring with PSG for adenotonsillectomy surgery (10-12).

The prevalence of SDB apparent across both the developmental spectrum and disease pathways produces no specific constellation of symptoms that is sufficiently sensitive to predict the presence of SDB in all children. OSA has several modifiable risk factors for which prompt diagnosis and management may prevent comorbidity associated with OSA. However, it is evident that the demand for pediatric PSG cannot be met (13) and alternative tools, including questionnaires (14,15), videos (16) and overnight oximetry (17), have been explored with limited success. In one centre, an abnormal pulse oximetry had a positive predictive value of 95% in determining OSA; however, many of the children in that study had normal oximetry and required formal PSG or repeat oximetry (17).
Given these limitations, a portable sleep monitor may be useful to screen and triage more medically urgent patients. The role of a portable sleep study (PSS) in children, either as a screening or diagnostic tool, has not been fully explored despite the fact that pediatric guidelines suggest that when a PSG is unavailable, other options, such as portable monitoring, should be used to best determine the likelihood of OSA (18).

One such PSS device, the ApneaLink (AL) monitor (ResMed, USA) has been validated in adults with a high sensitivity and specificity (19-21). The differences in the pathophysiology and management of SDB in children compared with adults does not allow for adult-specific data to simply be extrapolated to children. Recently, the AL monitor was evaluated in 25 obese adolescents (mean age 13 years) simultaneously with overnight PSG in a sleep laboratory and yielded a sensitivity and specificity of 85% and 83%, respectively, for apnea-hypopnea index (AHI) ≥5 events/h (22). However, the investigators did not include younger children, who are typically the more common at-risk age group for SDB.

The aim of the present study was to evaluate the utility of the AL monitor as a PSS for the diagnosis of SDB in children who typically present to a pediatric sleep facility. We hypothesized that the AL monitor could help in identifying children with moderate to severe SDB.

METHODS

Children four to <18 years of age with a history of snoring who were referred for an initial baseline PSG at The Hospital for Sick Children, Toronto, Ontario, from 2008 to 2010, were consecutively recruited for the present study. The Hospital for Sick Children is a tertiary referral centre and is the only designated pediatric sleep facility covering a large radius and, thus, receives many community referrals. Approximately 75% of referred children have underlying comorbidities. Children were excluded if they had previously received intervention before or during PSG (eg, adenotonsillectomy for OSA, oxygen or positive airway pressure therapy) or if they had ever had a PSG diagnosis of OSA. Children with known neurodevelopmental disorder were also excluded due to the lack of tolerability of PSG equipment, the burden of which would be increased with simultaneous PSS-AL monitoring.

The Research Ethics Board at The Hospital for Sick Children reviewed and approved the protocol, and subjects provided consent and assent before participating in the study.

Overnight PSG

All PSG studies were reported by pediatric sleep physicians who were blinded to the results of the PSS-AL. Patients underwent standard overnight PSG using a data acquisition and analysis system (XLTEK, Natus Medical Inc, USA). Respiratory measurements included chest wall and abdominal movements using chest wall and abdominal belts; nasal airflow measurements using nasal air pressure transducer and nasal thermal sensor; oxygen saturation using oximeter (Masimo Corporation, USA); transcutaneous carbon dioxide (tcCO2) and end-tidal carbon dioxide (etCO2). The PSG system used Braebon (Braebon Medical Corporation, Canada) QRIIP respiratory inductive plethysmography effort sensors, cannula connected to Braebon pressure transducer and Braebon Thermistor. The tcCO2 was recorded using Linde Microgus 7650 (Basel, Switzerland) and etCO2 was recorded using a capnograph (Capnocheck Sleep, BCI, USA). PSG measurements also included electroencephalogram, electro-oculogram, and submental and bilateral anterior tibialis electromyograms. Video and audio recordings were obtained for each study and body position. Sleep architecture was assessed using standard techniques (23). Information obtained from PSG included sleep- onset latency and rapid eye movement (REM) onset latency, total sleep time (TST), sleep efficiency, time spent in each sleep stage (minutes and percentage), number and classification of arousals, number of independent leg movements and snoring. Recorded respiratory data included counts and indexes of the following events: obstructive apneas, obstructive hypopneas, central apneas and mixed apneas. All events were scored according to the American Academy of Sleep Medicine (AASM) scoring guidelines for children (23) by a registered PSG technician who was blinded to the results of the PSS-AL. An obstructive apnea event was scored when airflow decreased >90% from baseline for at least 90% of the entire respiratory event with chest and/or abdominal movement throughout the entire event, the duration of which was at least a minimum of two baseline breaths. A hypopnea event was scored when airflow dropped by at least 50% from baseline, the duration of which was at least a minimum of two baseline breaths. The hypopnea event must have been accompanied by a minimum 3% drop in oxygen desaturation, an arousal or an awakening (23). A central apnea event was defined as a cessation of airflow with an absence of respiratory and abdominal effort for a minimum of 20 s or of the duration of at least two baseline breaths, in which case the event must be accompanied by a minimum 3% drop in oxygen desaturation, an arousal or an awakening. Central hypopneas were not evaluated. A mixed apnea event was scored when airflow decreased >90% from baseline for at least 90% of the entire respiratory event, the duration of which was a minimum of two baseline breaths, which is associated with absent inspiratory effort in the initial portion of the event, followed by resumption of inspiratory effort before the end of the event. SDB severity was graded according to accepted clinical criteria. The AHI was the number of obstructive apneas, hypopneas, mixed apneas and central apneas per hour during sleep. An AHI < 1.5 events/h was considered to be normal (24); an AHI from 1.5 events/h to <5 events/h was considered to be mild SDB; an AHI from 5 events/h to <10 events/h was considered to be moderate SDB; and an AHI ≥10 events/h was considered to be severe SDB.

AL monitor

The PSS monitor used was the AL device, which consists of a nasal cannula attached to a small case that houses a pressure transducer that monitors airflow. The monitor is held in place by a securing belt (the belt plays no role in the device monitoring). Pulse oximetry is also recorded via a digital probe with an averaging time of 1 s, which also monitors heart rate. Children who had <4 h of recorded data on the PSS-AL were withdrawn to prevent misclassification. Scoring of the PSS-AL was performed using the proprietary automated software algorithm (provided concurrently with AL). Automated software analysis used the following definitions: an apnea was defined as ≤20% flow relative to baseline; and a hypopnea was defined as ≤50% flow relative to baseline with 3% desaturation. The duration of each was based on overall computed baseline respiratory rate. The device does not account for mouth breathing and, thus, events are assumed to be apneas when flow limitation occurs. The device is able to identify the presence of a poor airflow signal and this was evaluated. The AL software also enables the investigator to undertake manual scoring, which was performed by a registered PSG technologist who was blinded to the results of the autoscore, clinical history and the overnight PSG results. Manual scoring of apneas and hypopneas used the 2007 AASM pediatric criteria as outlined above. The event classification was determined a priori by the study team. All respiratory events monitored by the PSS-AL were combined to derive an AHI, which was compared with the AHI obtained from PSG.

The present study was unfunded; however, the manufacturer (ResMed, USA) donated the device for the study and associated supplies. ResMed was not involved in any data collection, analyses or review of the manuscript.

Statistical analysis

A sample size of 25 was needed to detect a correlation coefficient of 0.60, which would exceed a two-tailed α = 0.05 and β = 0.10. The analyses were performed using SAS version 9.2 (SAS Inc, USA). Descriptive statistics, including frequencies, percentages, mean, median and/or range values, were obtained for all baseline demographics and PSG data. Frequency statistical analyses were used to observe the prevalence of SDB in this population. The PSS-AL monitor results were compared with the
reference standard PSG using Fisher's exact test for the classification of SDB severity. Sensitivity, specificity, and positive and negative predictive values for the manually scored PSS-AL were calculated using AHI cut-off values of \( \geq 1.5 \) events/h and \( \geq 5 \) events/h. Median values are reported because the data were not normally distributed.

Bland-Altman plots were used as a graphical representation of the observed differences between the paired measurements to examine the relationship between the magnitude and degree of variation in the AHI measurements using full PSG and the PSS-AL. Correlations between the AHI obtained from PSG and the manually scored PSS-AL, and between the automated and manual PSS-AL AHI were determined using Pearson's correlation coefficient and intraclass correlation.

**RESULTS**

Forty-five subjects enrolled in the study, of which complete data for the PSS-AL and PSG were available for 35 (13 female). Overall, 10 of 45 (22%) studies had to be excluded because of limited recording time (<4 h of TST) or because there was insufficient flow to accurately determine respiratory events. The loss of flow data, either due to artefact or the displacement of the nasal cannula, was 19% across the flow signals of all the children who were included in the study. The median age of the subjects was 11.0 years and the median body mass index (BMI) z-score was 0.67 (Table 1), with 10 of 35 children classified as obese, which was defined as a BMI z-score \( \geq 1.65 \). Underlying comorbidities of the subjects included sickle-cell disease (n=13); central nervous system tumours (n=3) and Arnold-Chiari malformation (n=2). The median AHI of the subjects was 1.2 events/h (range 0.0 to 50.8 events/h). There were no significant differences between patients with comorbidities and healthy children in terms of age, sex, BMI, snoring and AHI. The median sleep latency and REM latency were 14 min and 155 min, respectively. The median TST was 373 min and the percentage of TST in stage 1, 2, 3 and REM sleep were 4.6%, 51.2%, 28.2% and 15.6%, respectively.

Using an AHI of \( \geq 1.5 \) events/h to diagnose SDB, 18 of 35 (51%) subjects were classified with SDB and, of these, five of 17 (29%) had moderate to severe SDB (Table 2). There was a significant correlation between the AHI obtained by manual scoring of the PSS-AL and the PSG AHI (Pearson correlation r=0.89; P<0.001; intraclass correlation r=0.81 [Figure 1]). There was also a significant correlation between manually scored PSS-AL AHI and PSS automated scored AHI (Pearson correlation r=0.59; P=0.002; intraclass correlation r=0.57, [Figure 2]). The correlation between the automated PSS-AL AHI score and the PSG AHI was moderate (Pearson correlation r=0.36; P=0.03). Using a cut-off AHI of \( \geq 1.5 \) events/h, the manually scored PSS-AL monitor had a sensitivity of 94% and specificity of 16% to detect any SDB (AHI \( \geq 1.5 \) events/h) diagnosed by PSG (Table 3). Using a cut-off AHI of \( \geq 5 \) events/h, the manually scored PSS-AL monitor had a sensitivity of 94% and specificity of 61% to detect any SDB (AHI \( \geq 1.5 \) events/h) diagnosed by PSG and a sensitivity of 100% with a specificity of 40% to detect moderate to severe SDB diagnosed by PSG (Table 3). The Bland-Altman plot showed fair agreement between PSS-AL and PSG, with a mean difference of \( \pm 3.9 \) events/h (Figure 3). Of interest, one of the outliers experienced a large number of hypopneas and apneas recorded on the PSS-AL while he had extended periods of wakefulness documented on the PSG. The second outlier was a 14-year-old female with sickle-cell disease who experienced hypopneas almost exclusively associated with arousals and very few desaturations, accounting for the lower PSS-AL AHI (5.0 events/h) compared with the PSG (10.4 events/h).

**TABLE 1**

<table>
<thead>
<tr>
<th>Demographic and polysomnography data of enrolled subjects (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>11.0 (4.0–17.0)</td>
</tr>
<tr>
<td>Weight, kg</td>
</tr>
<tr>
<td>Height, cm</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
</tr>
<tr>
<td>Body mass index z-score</td>
</tr>
<tr>
<td>History of snoring, n (%)</td>
</tr>
<tr>
<td>Sleep efficiency, %</td>
</tr>
<tr>
<td>Mean SaO₂, %</td>
</tr>
<tr>
<td>Minimum SaO₂, %</td>
</tr>
<tr>
<td>Highest tcCO₂/eCO₂, mmHg</td>
</tr>
<tr>
<td>PSG, obstructive apnea-hypopnea index</td>
</tr>
<tr>
<td>PSG, central apnea index</td>
</tr>
<tr>
<td>PSG, hypopnea index</td>
</tr>
<tr>
<td>PSS-AL (manual scoring), apnea-hypopnea index</td>
</tr>
<tr>
<td>PSS-AL (automated scoring), hypopnea index</td>
</tr>
</tbody>
</table>

Data presented as median (range) unless otherwise indicated. etCO₂: End-tidal carbon dioxide; PSG: Polysomnography; PSS-AL: Portable sleep study-APneuLink (ResMed, USA); SaO₂: Oxygen saturation; tcCO₂: Transcutaneous carbon dioxide

**DISCUSSION**

The principal findings of the present study show that the PSS-AL monitor can identify SDB in children. The present study found that, using an AHI cut-off value of \( \geq 5 \) events/h on the manually scored PSS-AL, there was excellent sensitivity and moderate specificity for the diagnosis of SDB compared with PSG. The AL has been used for adults with OSA with excellent sensitivity and specificity (19-21,25), with one study (19) reporting a sensitivity of 91% and specificity of 95% for subjects with a diagnosis of OSA (AHI >15). The possible reasons for lower specificity in the current study compared with the adult study may be explained by a lower incidence of moderate to severe OSA in the current group; the tendency for children to experience less significant hypoxemia than adults, making it more difficult to delineate events in the absence of oxygen desaturations; the inability of the device to distinguish central versus obstructive apneas; and mouth breathing in children that may be mistaken for respiratory events with reduced airflow. A more recent study examining the utility of the multichannel AL device in obese adolescents (mean age 13 years) observed SDB in 19 of 25 subjects with a sensitivity and specificity of >80% using an obstructive AHI cut-off value >5 events/h (22). The reason for improved specificity in that study may be explained by the fact that obese adolescents represent a more homogenous population than the spectrum of patients that present to a pediatric sleep program with SDB. We also found that, compared with the PSG data, the PSS-AL underestimated the AHI, similar to Lesser et al (22), and incorrectly diagnosed patients as having SDB. Possible reasons for the overestimation of the AHI resulting in 'false positives' include events scored during wakefulness, reduced flow observed on a nasal flow channel during mouth breathing, even in the absence of apnea and/or postarousal artefacts mistaken as reduced airflow. The manual and automated PSS-AL scoring were comparable in diagnosing moderate to severe SDB when present but comparably misclassified the severity of SDB compared with PSG.

The limitations of the present study warrant consideration. The sample population included children who were referred to a tertiary pediatric sleep centre, which may limit the generalizability of these results to a community-based, nonreferred sample. We deliberately chose to include a spectrum of patients who were likely to present to pediatric programs to address the utility of such a device within a pediatric sleep facility. Moreover, there were no baseline or PSG differences between patients with comorbidities and healthy children in this group.

The PSS-AL cannot distinguish between central and obstructive apneas, which, together with the lack of electroencephalogram data, may result in misclassification of subjects. Additional limitations of portable monitors include missing data due to lack of application, malfunction and intolerance of the nasal cannula. The data loss...
reported in our study is comparable with that reported in other studies (19,22). Furthermore, the PSS-AL monitor was not used in a home setting; therefore, we are unable to determine its reliability and feasibility, although this has been reported in the adult literature (19,26). During the study, there were no adverse events from using this tool in the sleep laboratory. Because we did not study children <4 years of age, we are unable to comment on the tolerability and safety of these tools in very young children.

A PSG test is labour intensive, time consuming, expensive and can be particularly difficult to perform in children. Due to the ease of use and relatively inexpensive operating costs, portable sleep monitors offer promise as a screening tool for children to readdress the balance of inequity in the timely diagnosis and management of SDB. However, these portable monitors, given the listed limitations, should be used in the context of a pediatric sleep program with clinical evaluation for management of these patients.

**CONCLUSION**

The lack of timely diagnosis of sleep disorders in children limits the scope of potentially beneficial treatments. Given the long wait times for PSG, the single-channel AL monitor is a useful screening tool for triage in pediatric sleep laboratories, although it cannot and should not be used in the context of a pediatric sleep program with clinical evaluation for management of these patients.

**TABLE 2**

The apnea-hypopnea index (AHI) in subjects diagnosed using polysomnography and the PSS-AL monitor

<table>
<thead>
<tr>
<th>SDB according to the type of sleep study</th>
<th>Polysomnography</th>
<th>Manual PSS-AL</th>
<th>Automated PSS-AL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHI &lt;1.5 events/h</td>
<td>18 (51)</td>
<td>4 (11)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Mild SDB (AHI ≥1.5 events/h to &lt;5 events/h)</td>
<td>12 (34)</td>
<td>8 (23)</td>
<td>8 (23)</td>
</tr>
<tr>
<td>Moderate SDB (AHI ≥5 events/h to &lt;10 events/h)</td>
<td>1 (4)</td>
<td>12 (34)</td>
<td>12 (34)</td>
</tr>
<tr>
<td>Severe SDB (AHI ≥10 events/h)</td>
<td>4 (11)</td>
<td>11 (32)</td>
<td>14 (40)</td>
</tr>
</tbody>
</table>

Data presented as n (%). PSS Portable sleep study; PSS-AL Portable sleep study-ApneaLink (ResMed, USA); SDB Sleep disordered breathing

**TABLE 3**

Sensitivities and specificities of automated and manually scored PSS-AL AHI compared with PSG AHI

<table>
<thead>
<tr>
<th>PSS-AL AHI</th>
<th>PSG SDB (AHI ≥1.5 events/h)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>PSG SDB (AHI ≥5 events/h)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual PSS-AL (cut-off ≥1.5 events/h)</td>
<td>94</td>
<td>16</td>
<td>51</td>
<td>75</td>
<td>100</td>
<td>13</td>
<td>16</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manual PSS-AL (cut-off ≥5 events/h)</td>
<td>94</td>
<td>61</td>
<td>70</td>
<td>92</td>
<td>100</td>
<td>40</td>
<td>22</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Automated PSS-AL (cut-off ≥1.5 events/h)</td>
<td>94</td>
<td>0</td>
<td>47</td>
<td>0</td>
<td>100</td>
<td>3</td>
<td>15</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Automated PSS-AL (cut-off ≥5 events/h)</td>
<td>94</td>
<td>44</td>
<td>62</td>
<td>88</td>
<td>100</td>
<td>30</td>
<td>19</td>
<td>100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as %. AHI Apnea-hypopnea index; NPV Negative predictive value; PSG Polysomnography; PSS-AL Portable sleep study-ApneaLink (ResMed, USA); PPV Positive predictive value; SDB Sleep disordered breathing
not replace PSG. We recommend its use only in the context of an appropriate clinical evaluation. Future research is urgently needed to address the role of portable sleep monitors in home settings of otherwise healthy children in the community.

ACKNOWLEDGEMENTS: The authors are grateful to the children and families who participated in this study.

DISCLOSURES: This study was unfunded and the authors have no financial disclosures or conflicts of interest to declare.

REFERENCES